Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
MWN-AI** Summary
Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug development company focused on treating degenerative retinal diseases, has announced its participation in the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress, scheduled for February 5-7, 2026, in Hong Kong. The company will showcase topline results from its Phase 3 DRAGON study of tinlarebant, a novel oral therapy designed for adolescents suffering from Stargardt disease type 1 (STGD1), a condition marked by progressive vision loss due to retinal cell death.
At the congress, Belite Bio will host an oral presentation titled "Topline Results from the Phase 3 DRAGON Study of Tinlarebant for Adolescent Stargardt Disease," presented by Ruifang Sui, M.D., Ph.D., on February 6, 2026. This will be supplemented by case reports from the study that provide insights into individual patient experiences. Additionally, the company is organizing a sponsored lunch symposium featuring notable experts, including Hendrik Scholl, M.D., and Akiko Maeda, M.D., which will delve deeper into the clinical implications of tinlarebant.
Tinlarebant aims to mitigate the retinal disease's progression by reducing the buildup of harmful vitamin A derivatives known as bisretinoids. This therapy has already received several designations in the U.S. and in Japan, reflecting its potential significance in treating STGD1, which remains without FDA-approved therapies.
With its ongoing commitment to addressing unmet medical needs in ophthalmology, Belite Bio is not only advancing its clinical program but is also enhancing its visibility within the scientific community at the APAO Congress. Bellite Bio is also engaging with the broader community through social media and its corporate website to raise awareness about its groundbreaking research and therapeutic objectives.
MWN-AI** Analysis
Belite Bio, Inc. (NASDAQ: BLTE) stands at a pivotal moment as it prepares to participate in the upcoming 41st Asia-Pacific Academy of Ophthalmology Congress (APAO) from February 5-7, 2026. This event is set to spotlight the company’s lead therapeutic candidate, tinlarebant, a novel oral treatment for Stargardt disease type 1 (STGD1), a significant degenerative retinal condition with no existing FDA-approved therapies.
The company’s engagement at the APAO Congress through presentations of topline results from the Phase 3 DRAGON study is particularly compelling. Such high-profile conferences are hotbeds for scientific exchange and networking, and Belite's sponsorship of a lunch symposium indicates its intention to foster robust discussions around tinlarebant's mechanism and clinical implications. Investors should consider how these presentations can positively influence market perceptions regarding both the short- and long-term potential of Belite Bio.
The Breakthrough Therapy Designation and Orphan Drug Designation for tinlarebant signal FDA recognition of its potential, which typically garners investor interest and enhances stock momentum leading up to key developmental milestones. It’s important to monitor investor sentiment post-congress as the topline results could have significant implications for ongoing and future clinical trials, particularly as Belite seeks to address additional indications like geographic atrophy.
In terms of broader market strategies, while Belite Bio appears to have strong clinical development prospects, potential investors should remain cautious due to the inherent risks associated with clinical-stage companies. Monitoring the outcomes of the upcoming presentations, alongside broader market conditions in the biotech sector, will be crucial. It may be prudent to consider incremental investment or patience until more definitive data emerges, especially in light of the stock's volatility often associated with clinical trial announcements. Thus, while the near term may hold opportunities, strategic caution is advisable.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in the upcoming Asia-Pacific Academy of Ophthalmology (APAO) 2026 Congress, taking place February 5-7, 2026 in Hong Kong.
The presentations will include previously disclosed topline results from the Phase 3 DRAGON study of tinlarebant in adolescents with Stargardt disease type 1 (STGD1), as well as individual patient case reports from the study. Belite’s participation will include an oral presentation in a general scientific session, a sponsored lunch symposium, and an exhibition booth.
Presentation Details
Session: Inherited Retinal Disease and Miscellaneous Topics
Title: Topline Results from the Phase 3 DRAGON Study of Tinlarebant for Adolescent Stargardt Disease
Presenter: Ruifang Sui, M.D., Ph.D.
Date and Time: February 6, 2026, 3:40-3:50 p.m.
Location: Room S221, Hong Kong Convention and Exhibition Centre
Sponsored Lunch Symposium
Theme: Tinlarebant from Mechanism to Clinical Impact: Topline Results of the Phase 3 DRAGON Clinical Trial and Expert Insights
Speakers:
- Hendrik Scholl, M.D., M.A.
- Akiko Maeda, M.D., Ph.D.
- Quan Dong Nguyen, M.D., M.Sc., FAAO, FARVO, FASRS
- Ruifang Sui, M.D., Ph.D.
- Yih-Shiou Hwang, M.D., Ph.D.
Date and Time: February 7, 2026, 1:00-2:00 p.m.
Location: Room S423+S424, Hong Kong Convention and Exhibition Centre
Exhibition Booth
Dates: February 5-7, 2026
Location: Hall 5E, Booth 5E-C03
About Tinlarebant (a/k/a LBS-008)
Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in Stargardt disease type 1 (STGD1) and also contribute to disease progression in geographic atrophy (GA), or advanced dry age-related macular degeneration (AMD). Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Disease Designation in the U.S., Orphan Drug Designation in the U.S., Europe, and Japan, and Sakigake Designation in Japan for the treatment of STGD1.
About STGD1
STGD1 is the most common inherited macular dystrophy (causing blurring or loss of central vision) [in both adults and children]. The disease is caused by mutations in a retina-specific gene (ABCA4), which results in progressive accumulation of bisretinoids leading to retinal cell death and progressive loss of central vision. The fluorescent properties of bisretinoids and the development of retinal imaging systems have helped ophthalmologists identify and monitor disease progression. Currently, there are no FDA approved treatments for STGD1.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent STGD1 subjects and is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent STGD1 subjects and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu / ir@belitebio.com
Sophie Hunt / belite@argotpartners.com
FAQ**
What are the anticipated outcomes for Belite Bio Inc (BLTE) following the presentations at the APAO 2026 Congress regarding the Phase 3 DRAGON study results for tinlarebant?
How might Belite Bio Inc (BLTE) leverage the Breakthrough Therapy Designation for tinlarebant to expedite patient access to treatment for STGD1?
Given the absence of FDA-approved treatments for STGD1, what competitive advantages could Belite Bio Inc (BLTE) gain with the successful commercialization of tinlarebant?
What insights from the upcoming lunch symposium at the APAO 2026 Congress could enhance investor confidence in Belite Bio Inc (BLTE) and its clinical development strategies?
**MWN-AI FAQ is based on asking OpenAI questions about Belite Bio Inc (NASDAQ: BLTE).
NASDAQ: BLTE
BLTE Trading
-1.36% G/L:
$173.39 Last:
59,640 Volume:
$171.56 Open:
